$XBI $84.60 | +1.21%
Covid Updates
$MRNA -1.3% Moderna Announces Clinical Update on Bivalent COVID-19 Booster Platform. source
$NVAX -1.0% Novavax Announces Approval of Nuvaxovidâ„¢ COVID-19 Vaccine for Primary and Booster Immunization in Japan. source
Pipeline Updates
$GLSI +2.3% Greenwich LifeSciences Presents Phase IIb Data, Published at AACR 2022, Further Supporting the Role of GP2 in Preventing Metastatic Breast Cancer. source
$HGEN +1.3% Humanigen Announces Peer-Reviewed Publication Demonstrating the Potential Clinical and Economic Benefits of Lenzilumab from the Perspective of the NHS. source
$SWTX +3.0% SpringWorks Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Regeneron to Evaluate Nirogacestat in Combination with REGN5458 in Patients with Relapsed or Refractory Multiple Myeloma. source
$EGRX +1.9% Eagle Pharmaceuticals Reaches Settlement Agreement with Hospira Related to BENDEKA® (bendamustine hydrochloride) until January 17, 2028. source
$EVFM +1.7% Journal of Sexual Medicine Publishes Sexual Satisfaction Data Involving Phexxi® from Evofem's Phase 3 AMPOWER Clinical Trial. source
$ACET 0.0% Adicet Bio Receives FDA Fast Track Designation for Lead Candidate ADI-001. source
$FOLD +3.4% Amicus Announces Issuance of New U.S. Composition of Matter Patent for Galafold® (migalastat), Strengthening Patent Protection Through 2038. source
$AUPH -1.3% Aurinia Announces Year-Two Commitment to Patient Navigation Grant Program to Address Barriers for Individuals Living with Lupus and Lupus Nephritis. source
Business Updates
$BTAI +1.1% BioXcel Therapeutics Announces $260 Million Strategic Financing with Oaktree and Qatar Investment Authority. source
$REGN -1.0% Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types. source
$BTAI +1.1% BioXcel Therapeutics Announces Formation of OnkosXcel Therapeutics to Develop Medicines Focused in Oncology. source
$ALKS -1.5% Alkermes Commences Arbitration Related to License Agreements with Janssen Pharmaceutica. source
Posted by FS/JM